BioNTech (NASDAQ:BNTX) Coverage Initiated by Analysts at Truist Financial

Truist Financial started coverage on shares of BioNTech (NASDAQ:BNTX) in a report issued on Friday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $172.00 price objective on the stock.

BNTX has been the subject of a number of other reports. BMO Capital Markets reissued an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and raised their price target for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. UBS Group upped their price objective on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research report on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and set a $150.00 target price on shares of BioNTech in a research report on Monday, November 18th. Finally, Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $93.00 to $145.00 in a report on Tuesday, September 24th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Stock Up 0.6 %

BioNTech stock opened at $122.85 on Friday. The firm has a market capitalization of $29.45 billion, a price-to-earnings ratio of -58.50 and a beta of 0.18. The firm’s fifty day moving average price is $114.07 and its two-hundred day moving average price is $103.06. BioNTech has a 1-year low of $76.53 and a 1-year high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s quarterly revenue was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.73 EPS. On average, equities research analysts predict that BioNTech will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fred Alger Management LLC purchased a new stake in shares of BioNTech during the 3rd quarter valued at approximately $59,485,000. Baillie Gifford & Co. lifted its position in shares of BioNTech by 0.4% during the third quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after acquiring an additional 31,773 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of BioNTech by 63.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 18,939 shares of the company’s stock worth $2,249,000 after acquiring an additional 7,340 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of BioNTech by 123.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after purchasing an additional 74,119 shares in the last quarter. Finally, Discovery Capital Management LLC CT bought a new stake in shares of BioNTech during the 2nd quarter valued at $2,467,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.